Actively Recruiting

Phase Not Applicable
Age: 18Years - 80Years
All Genders
NCT02097758

Efficacy of Three Dimensional Transesophageal Echocardiography for Percutaneous Device Closure in Atrial Septal Defect

Led by Asan Medical Center · Updated on 2025-02-07

100

Participants Needed

1

Research Sites

665 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Background: Three-dimensional echocardiographic image for atrial septal defect (ASD) is useful for evaluation of defect size and shape. The investigators suggested optimal device size using three-dimensional transesophageal echocardiographic image and our formula in previous study. Purpose: In this study, the investigators seek to predict the correct device size and confirm the accuracy of the formula that we made before device closure in ASD patients.

CONDITIONS

Official Title

Efficacy of Three Dimensional Transesophageal Echocardiography for Percutaneous Device Closure in Atrial Septal Defect

Who Can Participate

Age: 18Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or older
  • Indication for atrial septal defect closure
  • Potential candidate for device closure
Not Eligible

You will not qualify if you...

  • Poor candidate for device closure due to multiple atrial septal defects or similar conditions
  • Presence of other heart diseases needing open heart surgery

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Asan Medical Center

Seoul, South Korea, 138-736

Actively Recruiting

Loading map...

Research Team

J

Jong-Min Song, MD,PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

DIAGNOSTIC

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here